Loading…

Multiple Site Hydrogen Isotope Labelling of Pharmaceuticals

Radiolabelling is fundamental in drug discovery and development as it is mandatory for preclinical ADME studies and late‐stage human clinical trials. Herein, a general, effective, and easy to implement method for the multiple site incorporation of deuterium and tritium atoms using the commercially a...

Full description

Saved in:
Bibliographic Details
Published in:Angewandte Chemie International Edition 2020-11, Vol.59 (47), p.21114-21120
Main Authors: Daniel‐Bertrand, Marion, Garcia‐Argote, Sébastien, Palazzolo, Alberto, Mustieles Marin, Irene, Fazzini, Pier‐Francesco, Tricard, Simon, Chaudret, Bruno, Derdau, Volker, Feuillastre, Sophie, Pieters, Grégory
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Radiolabelling is fundamental in drug discovery and development as it is mandatory for preclinical ADME studies and late‐stage human clinical trials. Herein, a general, effective, and easy to implement method for the multiple site incorporation of deuterium and tritium atoms using the commercially available and air‐stable iridium precatalyst [Ir(COD)(OMe)]2 is described. A large scope of pharmaceutically relevant substructures can be labelled using this method including pyridine, pyrazine, indole, carbazole, aniline, oxa‐/thia‐zoles, thiophene, but also electron‐rich phenyl groups. The high functional group tolerance of the reaction is highlighted by the labelling of a wide range of complex pharmaceuticals, containing notably halogen or sulfur atoms and nitrile groups. The multiple site hydrogen isotope incorporation has been explained by the in situ formation of complementary catalytically active species: monometallic iridium complexes and iridium nanoparticles. A general method for the multiple site hydrogen isotope labelling of complex molecules using the commercially available and air‐stable iridium precatalyst [Ir(COD)(OMe)]2 is reported. This new synthetic method possesses multiple key features far beyond the state‐of‐the‐art methods for tritium labelling, including a very broad substrate scope and an exceptional functional group tolerance facilitating the access to complex pharmaceuticals with high molar activities.
ISSN:1433-7851
1521-3773
DOI:10.1002/anie.202008519